ArticlemBio2017
A Novel Small-Molecule Inhibitor of the
Open access · goldAbstract read
In one paragraph
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 88 citations in OpenAlex.
- A Series of Pyrazolo-Quinazoline Amines Inhibits the CytochromeJournal of medicinal chemistry · 2026Article
- Menaquinone depletion resensitises bedaquiline-resistant tuberculosis.bioRxiv : the preprint server for biology · 2026Article
- Essential redundancies fuel Mycobacterium tuberculosis adaptation to the host.PLoS pathogens · 2025Review
- Biofilm development ofMicrobiology spectrum · 2025Article
- Usnic acid impacts energy production and iron metabolism inmSystems · 2025Article
- Evolution of Small Molecule Inhibitors ofJournal of medicinal chemistry · 2025Article
- Unraveling bacterial stress responses: implications for next-generation antimicrobial solutions.World journal of microbiology & biotechnology · 2024Article
- SAR study of piperidine derivatives as inhibitors of 1,4-dihydroxy-2-naphthoate isoprenyltransferase (MenA) from Mycobacterium tuberculosis.European journal of medicinal chemistry · 2023Article
- Allosteric inhibition ofPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Article
- Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs.Antimicrobial agents and chemotherapy · 2022Article
- Article
- Rifampicin-Mediated Metabolic Changes inMetabolites · 2022Article
- Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species.Microbial biotechnology · 2022Article
- Multiplexed transcriptional repression identifies a network of bactericidal interactions between mycobacterial respiratory complexes.iScience · 2022Article
- Understanding the contribution of metabolism toFrontiers in cellular and infection microbiology · 2022Review
- Uncovering interactions between mycobacterial respiratory complexes to target drug-resistantFrontiers in cellular and infection microbiology · 2022Review
- The evolving biology ofFrontiers in cellular and infection microbiology · 2022Review
- Insights into the molecular determinants involved inVirulence · 2021Review
- Metabolic Versatility ofMetabolites · 2021Review
- Mycobacterium tuberculosis Rv3160c is a TetR-like transcriptional repressor that regulates expression of the putative oxygenase Rv3161c.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Paridhi SukhejaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Pradeep KumarDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Nisha MittalDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Shao-Gang LiDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Eric SingletonDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Riccardo RussoDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Alexander L PerrymanDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Riju ShresthaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Divya AwasthiDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Seema HusainGenomics Center, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Patricia SoteropoulosGenomics Center, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Roman BrukhDepartment of Chemistry-Rutgers University-Newark College of Arts and Sciences, Newark, New Jersey, USA.
Nancy ConnellDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Joel S FreundlichDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
David AllandDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA david.alland@rutgers.edu.
Rutgers New Jersey Medical SchoolRutgers, The State University of New Jersey · US
Funding
Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DARTOIS, VERONIQUE · 2014 to 2018
$26.9MDiscovery and Validation of Drug Targets in Vulnerable PopulationsR33AI111647 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID · 2016 to 2018
$1.5MDiscovery and validation of drug targets in vulnerable pathways of MtbR21AI111647 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID · 2014 to 2015
$437kNIAID NIH HHS R21 AI111647NIAID NIH HHS R33 AI111647NIAID NIH HHS U19 AI109713
Abstract
Active tuberculosis (TB) and latent
Indexed as
Drug DiscoveryAdenosine TriphosphateAntitubercular AgentsBiphenyl CompoundsDrug Resistance, BacterialHumansMethyltransferasesMicrobial Sensitivity TestsMycobacterium tuberculosisSmall Molecule LibrariesVitamin K 2Adenosine TriphosphateAntitubercular AgentsBiphenyl CompoundsdemethylmenaquinoneMethyltransferasesSmall Molecule LibrariesVitamin K 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.